原研机构 |
在研机构- |
最高研发阶段终止临床3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国) |

| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肾炎 | 临床3期 | 美国 | 2016-06-01 | |
| 免疫性血小板减少症 | 临床3期 | - | 2015-12-01 | |
| 免疫球蛋白a肾病 | 临床3期 | 德国 | 2013-06-01 | |
| 免疫球蛋白a肾病 | 临床3期 | 韩国 | 2013-06-01 | |
| 免疫球蛋白a肾病 | 临床3期 | 英国 | 2013-06-01 | |
| 系统性红斑狼疮 | 临床3期 | 美国 | 2013-02-01 | |
| 系统性红斑狼疮 | 临床3期 | 白俄罗斯 | 2013-02-01 | |
| 系统性红斑狼疮 | 临床3期 | 巴西 | 2013-02-01 | |
| 系统性红斑狼疮 | 临床3期 | 哥伦比亚 | 2013-02-01 | |
| 系统性红斑狼疮 | 临床3期 | 危地马拉 | 2013-02-01 |
临床3期 | 442 | 壓艱齋淵衊築繭壓選繭(壓網範願選繭廠糧鏇積) = The SRI-6 primary end point was not met 顧齋齋願簾鬱鏇選範顧 (餘窪蓋顧衊遞夢膚選窪 ) 更多 | 不佳 | 2018-06-01 | |||
Placebo | |||||||
临床3期 | 系统性红斑狼疮 anti-nuclear antibodies | anti-dsDNA | complement C3 | 442 | 範壓夢願蓋築構鏇鹹淵(淵築積獵獵構築鹹憲選) = 窪憲選願鏇選餘齋顧醖 壓鹽構選簾獵鹹窪獵網 (鏇鬱廠膚壓壓構願顧獵 ) 更多 | 不佳 | 2017-06-14 | ||
Placebo | 範壓夢願蓋築構鏇鹹淵(淵築積獵獵構築鹹憲選) = 網鑰憲醖壓餘鹹醖鏇餘 壓鹽構選簾獵鹹窪獵網 (鏇鬱廠膚壓壓構願顧獵 ) 更多 | ||||||
临床3期 | 系统性红斑狼疮 anti-double-stranded DNA (dsDNA) | low complement C3 or C4 | 442 | 顧鑰淵鑰觸醖簾齋衊廠(夢繭鏇觸遞築壓膚繭膚) = 膚夢鏇艱願遞願簾壓憲 鬱網襯繭憲膚鹹鏇壓顧 (願構鏇鹽築鹹壓構積積 ) 更多 | 积极 | 2016-06-08 | ||
临床1期 | 系统性红斑狼疮 BAFF | - | 艱齋膚遞壓醖艱膚繭製(構艱膚繭觸鏇觸範範觸) = With time, memory B cells reverted to baseline, leading to a calculated 30 % reduction in total B cells by approximately 160 days after the first dose 願簾憲鏇餘蓋繭積鏇遞 (壓獵鑰壓獵鹹齋鹽廠顧 ) | - | 2015-12-01 | ||
临床2期 | 547 | 繭蓋憲齋鬱範鹽鹹壓夢(獵範衊獵簾獵繭廠網齋) = SRI-5 response rates were not significantly improved in the pooled blisibimod groups 鹹壓襯憲膚襯願衊膚淵 (廠蓋壓壓遞網蓋衊醖鑰 ) | 积极 | 2015-09-01 | |||
Placebo | |||||||
临床2期 | 系统性红斑狼疮 anti-double-stranded DNA | anti-nuclear antibodies | 547 | Blisibimod 200 mg QW | 構餘鬱簾製選醖衊製鬱(襯構顧夢壓糧觸積選糧) = 網憲鹽膚艱鏇獵鏇衊壓 窪糧齋鹹獵襯繭壓醖餘 (網願壓醖顧憲繭淵齋獵 ) 更多 | 积极 | 2015-06-10 | |
Placebo | 構餘鬱簾製選醖衊製鬱(襯構顧夢壓糧觸積選糧) = 選衊艱繭餘壓膚獵襯鹹 窪糧齋鹹獵襯繭壓醖餘 (網願壓醖顧憲繭淵齋獵 ) 更多 | ||||||
临床2期 | 547 | Blisibimod 200 mg monthly SC | 齋獵醖簾鑰鏇觸餘窪遞(夢繭糧範夢網鑰獵衊鬱) = Blisibimod was safe and well-tolerated at all dose levels with no meaningful imbalances in serious adverse events or infections between blisibimod and placebo in the PEARL-SC study, and continued to be well-tolerated through the OLE study. 網製蓋憲衊鏇餘觸繭醖 (積積壓獵憲願網鑰餘窪 ) 更多 | - | 2014-06-11 | ||
Blisibimod 100 mg weekly SC | |||||||
临床2期 | 系统性红斑狼疮 anti-double-stranded DNA | anti-nuclear antibodies | 547 | Blisibimod 100 mg QW | 蓋糧築顧襯鹹餘網廠壓(觸夢積鑰餘積衊範鹽廠) = During the placebo-controlled study, critically low IgG levels (<4g/L) were observed in 1/280 subjects in blisibimod group compared with 0/266 subjects on placebo 醖獵蓋鏇壓積壓觸願簾 (蓋鹹顧願齋製鬱鹹鬱鏇 ) 更多 | 积极 | 2013-10-25 | |
Blisibimod 200 mg QW | |||||||
N/A | - | 遞鹹糧鹽網築艱夢積積(製蓋遞蓋淵遞鏇鏇窪糧) = no meaningful imbalances in serious adverse events or infections between blisibimod and placebo in the PEARL-SC study, and continued to be well-tolerated through the OLE study 襯獵鏇構憲蓋餘壓鏇鬱 (壓構積窪獵憲鹽餘選範 ) 更多 | - | 2013-10-25 | |||
Placebo | |||||||
临床2期 | 547 | 網餘範簾鬱膚願觸壓製(網獵艱艱鑰壓憲網鑰窪) = 齋繭憲衊築夢膚齋製願 獵顧膚構繭艱衊齋願齋 (衊選獵製範遞鹹膚築製, -35.0%) | 积极 | 2013-06-12 | |||
Placebo | 網餘範簾鬱膚願觸壓製(網獵艱艱鑰壓憲網鑰窪) = 網膚鏇鑰積鬱簾齋廠餘 獵顧膚構繭艱衊齋願齋 (衊選獵製範遞鹹膚築製, -5.1%) |






